Benefits
Immune support
In an individual participant data meta-analysis of 25 randomized trials and 11,321 participants (Martineau 2017), people taking vitamin D had fewer acute respiratory tract infections, adjusted odds ratio 0.88 (95% CI 0.81 to 0.96). That is a modest effect, and it was concentrated in participants who were profoundly deficient at the start, with baseline 25(OH)D below 25 nmol/L, adjusted odds ratio 0.30 (0.17 to 0.53). Dosing pattern mattered: participants who received one or more large bolus doses showed no significant benefit, adjusted odds ratio 0.97 (0.86 to 1.10). Only daily or weekly dosing produced the effect. This analysis did not test Aqua-D3.
Bone health background (no bone outcome was measured in the cited study)
This is general nutrition background, not a finding from the study cited on this page. Vitamin D is required for the gut to absorb calcium, and calcium is the mineral the skeleton is built from. No skeletal outcome of any kind was measured in the one reference listed here, so this page carries no skeletal evidence for vitamin D3 in general or for Aqua-D3 in particular.
Whole-body wellness (uncited on this page)
Vitamin D receptors are present in many tissues, which is why the vitamin is studied across a wide range of areas. No reference on this page examined muscle, mood, or metabolic outcomes, so treat this as uncited context rather than a demonstrated effect of this product.
Mechanism of action
Calcium absorption
Vitamin D enables the gut to absorb calcium and phosphorus, the minerals needed to build and maintain bone.
Immune modulation
Vitamin D supports both the innate and adaptive immune systems, helping the body respond appropriately to infection.
Clinical trials
Systematic review and meta-analysis of individual participant data covering 25 randomized controlled trials and 11,321 participants, with individual data available for 10,933 of them (96.6%). (Martineau et al. 2017, BMJ) The analysis does not name Aqua-D3 or any other branded water-dispersible form.
Adults and children, 11,321 participants across 25 trials, including a subgroup whose baseline 25(OH)D was below 25 nmol/L.
Vitamin D supplementation was associated with fewer acute respiratory tract infections overall, adjusted odds ratio 0.88 (95% CI 0.81 to 0.96), a modest effect. The largest reduction was in participants whose baseline 25(OH)D was below 25 nmol/L, adjusted odds ratio 0.30 (0.17 to 0.53). Participants who received one or more bolus doses showed no significant benefit, adjusted odds ratio 0.97 (0.86 to 1.10), so the effect was seen only with daily or weekly dosing. The authors reported that supplementation was safe. No bone or skeletal outcome was measured.